News Hub | News Direct

M2Bio Sciences Division M2Biome Cardiometabolic Health Launches Website

Institute of Biomedical Research Corp.

Institute of Biomedical Research (OTC: MRES) ("M2Bio Sciences'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update: M2Biome, a division of M2Bio Sciences, is pleased to announce the launch of its website. The website has been set up to serve healthcare professionals and health consumers alike. Sections include a health blog, called ‘Digestible Facts’, educational resources, recipes, and more. One key feature of the website includes a diabetes screening tool on the home page, which will notify people of their risk of having undiagnosed type 2 diabetes (T2DM) and prompt them to undergo further tests. This is also a valuable tool for highlighting the lifestyle changes that are needed to reduce the risk of developing T2DM and other non-communicable diseases that have similar underlying pathophysiology. Part of the M2Biome mission is to provide education on health and nutrition, and create awareness of the risk of disease. “The prevalence of undiagnosed diabetes in South Africa is estimated to be in the region of 45%. Unfortunately, many people are only diagnosed once they have developed complications, which has a huge impact on the quality of life and the cost of managing these individuals. As type 2 diabetes is largely preventable and manageable, I am passionate about creating awareness of risk. I am currently working on further validating the African Diabetes Risk Score to make it more generalizable in the South African population. ”, says Nicola Royce, Managing Director of M2Biome. The recipe section will be the ultimate user-friendly guide to very practical and easy-to-prepare healthy dishes. Each recipe will also serve as an opportunity to educate on the nutritional content of the dish. You will also learn how to make use of simple cooking methods to get the most out of the least ingredients. The recipes are divided into breakfast, lunch, dinner, dessert, snacks, condiments, and drinks for easy access to your needs. Icons have been developed to guide you in meeting your special dietary requirements with confidence. "Food should be fun, functional, and user-friendly. If you cannot make it, you cannot eat it. It is unacceptable for good produce to go to waste because it is too difficult to make the most of it. Never should any ingredient be used or abused to end up being unhealthy. Cooking should be easy and done in such a way that the end result is multi-beneficial. ", says Wilna Eksteen, Cardiometabolic Product Developer. M2Biome is also developing a Registered Dietitian database for health consumers to seek individualized treatment. While there are some basic principles when it comes to nutrition, there is no ‘blanket’ approach when applying medical nutrition therapy for various conditions. It is important for people to consult a Registered Dietitian to receive an individualized and tailored approach that takes religious requirements, life cycle stage, and dietary requirements and preferences into account. ‘’In line with an individualized approach, M2Biome will be incorporating Artificial Intelligence and Machine Learning for better patient outcomes. Machine learning takes large amounts of data to uncover patterns and insights related to dietary choices, health outcomes, and nutritional needs. Leveraging machine learning algorithms assists with developing personalised nutrition recommendations based on individual factors such as age, gender, activity level, and health conditions, leading to more tailored and effective dietary interventions. This will all be incorporated into an interactive model that assists individuals with ‘health nudges’ by generating meal plans, recipes to go with these meal plans, and even recommendations of where and what to eat, based on their requirements. Individuals can insert their daily activities, which will be documented and made available to their healthcare practitioners. Any health developments are recorded, which assists with adjusting recommendations and advising on any drug and nutrient interactions that should be remedied. This is all really the tip of the iceberg, and the sky appears to be the limit with all of the ‘smart’ technology we have in our lives today and how it can be used to connect the dots to help us lead healthier lives. This new interactive platform is going to be epic!’’ says Jeff Robinson, M2Bio Sciences CEO. About Institute of Biomedical Research Corp./ DBA M2Bio Sciences Institute of Biomedical Research Corp, is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "MRES". Contact: Website: www.m2biome.com E-mail: m2biome@m2bio.co Phone: +27 72 333 2148 Visit us on social media: Facebook Twitter LinkedIn Instagram Forward-Looking Statements: Safe Harbour Statement: In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences to include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency, and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements. Contact Details Institute of Biomedical Research Corp. m2biome@m2bio.co Company Website http://www.m2biome.com/

May 25, 2023 08:30 AM Eastern Daylight Time

Home "SMART" Home

News Media Group, Inc.

Contact Details Karl Wayne +1 334-440-6397 karl@newsmg.com Company Website https://newsmg.com/

May 25, 2023 06:00 AM Eastern Daylight Time

Video

Ripken Baseball® to Host All-Ripken Softball Games in Elizabethtown, Kentucky from July 27-30

Ripken Baseball

Ripken Baseball®, the leader in youth sports events and facilities, has expanded its All-Ripken brand by creating All-Ripken Softball. The inaugural All-Ripken Softball Games will attract top youth softball players nationwide to compete at The Ripken Experience® Elizabethtown in Kentucky from July 27-30, 2023. Softball players must be nominated by their peers and coaches for the opportunity to train the Ripken Way, compete against elite young athletes, and participate in a world-class youth softball experience. As part of the 4-day event, participating players will receive instructional opportunities led by professional softball players from the Florida Vibe. The All-Ripken Softball players will also witness the Florida Vibe and Team Alliance take the field to play head-to-head in the Softball Exhibition Series, which is scheduled to take place at Elizabethtown Sports Park on July 27, 28, and 29. To be eligible to participate in All-Ripken Softball, players must be in high school graduation classes between the Class of 2026 and the Class of 2033 and exhibit an elevated level of softball knowledge, dedication, sportsmanship, and skill. “One of our core values at Team Alliance is to bring together multiple generations of players who share a passion for the sport of softball,” said Jami Lobpries, Ph.D., CEO of Alliance Fastpitch. “We are honored to be part of the All-Ripken Softball Games to bring together youth, college, and pro players and grow the sport for the next generation. Softball teaches important lessons on the field that players can apply to all aspects of their lives off of it.” “At the Florida Vibe, we are witnessing tremendous growth in the professional space of softball as a result of high-profile events at the youth level like the All-Ripken Softball Games,” said Ryan Moore, CEO of Florida Vibe Athletics, Inc. “This event is a shining example of the game’s evolution, and we are thankful to Ripken Baseball for creating this platform.” To nominate and register a player for the All-Ripken Softball Games, parents, coaches, and leagues can visit https://ripkenbaseball.com/all-ripken-softball/ or email questions to scout@allripken.com. About Ripken Baseball Ripken Baseball brings teammates, coaches, and families together through its Big League Experiences while teaching children how to play sports the right way – the Ripken Way. Ripken Baseball continues to innovate the game through tournaments, camps, clinics, and spring training at their state-of-the-art baseball and softball facilities – The Ripken Experience ® Aberdeen (Maryland), The Ripken Experience ® Myrtle Beach (South Carolina), The Ripken Experience ® Pigeon Forge (Tennessee), The Ripken Experience ® Elizabethtown (Kentucky), Sports Force Parks at Cedar Point Sports Center (Ohio), and Cooperstown All Star Village (New York). Ripken Baseball also brings its youth sports experience to satellite locations through Ripken Select Tournaments. Learn more at ripkenbaseball.com. Contact Details Eric PR & Marketing, LLC Eric Nemeth nemeth@ericpr.com Company Website http://allripkensoftball.com/

May 24, 2023 04:23 PM Eastern Daylight Time

National Association of REALTORS® Housing Market Update: Spring Homebuying Season Shows Steady Demand

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/ISQQ6BDbGW0 With the spring buying season in full swing, many Americans are contemplating whether it’s a good time to buy or sell a home. Higher mortgage rates and relentless competition for the few houses on the market are some of the many reasons sellers and buyers should work with an agent who is a REALTOR® to find the right home and negotiate the terms of sale. In fact, according to NAR: Overall, home sales are trying to recover, but they’re heavily influenced by interest rates. Existing-home sales will drop 9.3% this year compared to 2022 but will increase by 15.4% next year. The typical seller receives 3.1 offers on their home, and 33% of homes are selling above list price. NAR expects prices will stabilize, dropping 1.8% this year before improving 2.8% in 2024. Median existing-home prices will mostly stabilize – with the national median existing-home price decreasing by 1.8% in 2023, to around $380,000. Sales in the second half of the year should be notably better than the first half as job gains continue and more favorable mortgage rates are expected. Housing inventory is also expected to remain tight in 2023, with housing starts below historical averages. However, housing starts will increase by 6.9% in 2024. As the market continues to shift, it is important to consult an expert real estate agent who can provide essential guidance to help consumers navigate the homebuying and selling process. In fact, 91% of homebuyers say they would engage their agent again or recommend them to others. Agents who are REALTORS® not only help people achieve the dream of homeownership but also help them create long-term wealth and financial stability for their family. Over the past decade, the median-priced home in the U.S. gained nearly $200,000 in value, making the typical homeowner 40 times wealthier than if they had remained a renter. Additionally, homeowners who benefited from home price appreciation in the last decade saw their debt decrease by 21%. If you’re looking for a REALTOR ® in your area, visit REALTOR.com. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

May 24, 2023 02:00 PM Eastern Daylight Time

Video

ChillWell Launches ChillWell 2.0 Portable Air Cooler for Personal Space Chilling Benefits

Cosmic Wave

FOR IMMEDIATE RELEASE Contact: ChillWell Phone: 888-998-6324 Email: chillwell@rephelpdesk.com CHILLWELL LAUNCHES CHILLWELL 2.0 PORTABLE COOLER WITH INSTA-FROST TECHNOLOGY AT 55% DISCOUNT FOR A COMFORTABLE, COOL SUMMER New portable cooler decreases indoor air temperatures in minutes while helping save hundreds on utility and cooling bills FAIRFIELD, New Jersey – May 24, 2023 – Portable cooler company ChillWell has launched ChillWell 2.0, a new and improved version of its flagship product. Made with advanced Insta-Frost technology, ChillWell 2.0 can keep homes cool and comfortable all summer long. Insta-Frost uses the proven power of evaporative cooling to reduce the temperature of the air while adding moisture, helping homes stay cool, comfortable, and hydrated. ChillWell is promoting the new portable air cooler through a special 50% off promotion. For a limited time, you can buy ChillWell 2.0 for just $89.99 per unit. “ChillWell 2.0 is our most advanced portable cooler yet,” explains a company spokesperson. “Our team developed Insta-Frost to rapidly cool indoor air temperatures in small and medium-sized spaces, and it works as advertised to help anyone stay cool and comfortable.” Backed by a 60 day moneyback guarantee, ChillWell 2.0 is also designed to be more portable than any other cooler on the market. The cooler has a rechargeable battery, allowing it to be used away from an immediate power source. Simply plug in ChillWell 2.0 via USB-C to charge it, then use the portable carrying handle to take it anywhere it needs to go. ChillWell 2.0 has scored top marks from industry experts for its ability to rapidly cool any space. Instead of waiting for a whole home HVAC system to kick into action, customers can start to feel cool air within minutes. “Insta-Frost uses an innovative, evaporation-based system with cooling cartridges to rapidly cool the air. Within minutes of turning it on, it starts to blow cool air across the room. We also encourage customers to add ice cubes to the water container, or place the included cooling cartridge in the freezer, for optimal cooling power.” Other unique features of ChillWell 2.0 include the multi-colored LED night lights, charging light indicators, and convenient carrying handle. ChillWell 2.0 is about more than helping customers stay cool all summer; it’s also about helping customers save money on home cooling and utility bills: “We’ve heard reports of customers reducing summer utility bills by $500 or more by using ChillWell 2.0 regularly. Instead of paying to cool an entire home, our customers can cool a specific room or space – all without permanently installing an AC system or running hoses through a window.” Customers who buy multiple ChillWell 2.0 portable coolers online today can save even more. ChillWell has dropped the price as low as $67.50 per cooler when ordering four coolers as part of the summer 2023 promotion. About ChillWell: ChillWell, found online at ChillWellShop.com, is a portable cooler company best-known for its flagship lineup of portable coolers. The company recently launched ChillWell 2.0 at a 55% discount for a limited time. The new and improved portable cooler features a rechargeable battery, convenient handle, and Insta-Frost technology for maximum cooling power. For more information, visit ChillWellShop.com. ### Contact Details Melissa Isabel +1 530-418-8423

May 24, 2023 01:35 PM Eastern Daylight Time

BioNTech's mRNA Vaccine Shows Early Potential Against Pancreatic Cancer

MarketJar

One of the most stubborn, deadly cancers is pancreatic cancer. What if individualized mRNA vaccinations could support the immune system's defense? One of the deadliest forms of cancer around, pancreatic cancer is estimated to kill 88% of patients. It’s also one of the most recurrent cancers, with roughly 90% of patients experiencing a relapse within seven to nine months after surgery. Fortunately, a recent study of an mRNA vaccine for pancreatic cancer patients has provided a glimpse of hope. Scientists at Memorial Sloan Kettering (MSK) Cancer Center in New York just published the results of a small study that the group conducted in partnership with Germany’s BioNTech on pancreatic cancer patients over several years. The study used a pancreatic cancer mRNA vaccine tailored to each patient’s tumor to potentially help provoke an immune response. What’s revolutionary about the vaccines is that the German scientists tailored them to the mutated proteins on the surface of cancer cells instead of a mix of tumor and normal cells, which has been the method tried for decades. The cells were extracted from patients’ tumors by researchers at Memorial Sloan and sent to BioNTech, the company that created the highly-effective COVID-19 vaccine alongside Pfizer. Among the participants in the study, half of the patients’ immune systems learned how to recognize and fight off the cancer cells and showed no signs of relapse during the 18 months they were tracked. While promising, personalized mRNA cancer vaccines are still in their infancy and are too costly to be broadly used. Right now, regular cancer screening remains the best method for detecting cancers, however there are currently no screening tests for pancreatic cancer. Fortunately, that could soon change thanks to Mainz Biomed (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer Developing Early Screening Tests for Colon and Pancreatic Cancers On May 10, Mainz Biomed announced a partnership with Microba Life Sciences for the creation of PancAlert in addition to early colon cancer diagnostics. The technical characteristics of a novel pancreatic cancer screening test with DNA and microbiota indications should be enhanced. As part of the agreement, the two companies will conduct a pilot research project utilizing Microba’s proprietary metagenomic sequencing technology and bioinformatic tools in an effort to discover novel microbiome biomarkers to detect pancreatic cancer. The project, which is expected to run until late 2023, will use Microba's Community Profiler (MCP), a proprietary metagenomic platform technology that has proven to be a best-in-class research tool that can produce comprehensive and accurate species profiles of gastrointestinal samples. Mainz Biomed (NASDAQ:MYNZ) is also focused on commercializing its flagship product ColoAlert, a highly efficacious and simple-to-use detection test for colorectal cancer (CRC) that is already available in select international territories. In Q1 2023, the company also launched a corporate health program in Germany by integrating into BGM, a well-established corporate health program that provides services to employees at 48 of the 50 largest companies in Germany. On May 24, Mainz Biomed announced initial results from its colorectal cancer screening campaign with Zöller-Kipper GmbH through its BGM partnership. In April 2023, Zöller-Kipper selected ColoAlert for its corporate health program, which includes over 2,500 employees. According to the results, employees found the online patient portal easy-to-use and convenient and were able to readily access the portal, request a kit and securely receive results within five days. In order to process the ColoAlert PCR test kit, Mainz Biomed has added Eurofins GeLaMed to its network of lab partners. Eurofins GeLaMed is a division of the global laboratory company Eurofins Scientific, which conducts 450 million tests annually and has over 61,000 employees in 61 nations. Germany is home to four of its locations. Advancing Towards FDA Approval to Bring ColoAlert to the US Market Over the last few months, Mainz Biomed has continued to prepare for patient enrollment in its pivotal clinical trial for ColoAlert after successfully completing its pre-submission process with the FDA. ColoAlert will be examined in the FDA-registered trial "ReconAAsense" in order to obtain commercial approval in the United States. The company's business objective is to create scalable distribution across the nation once it receives approval through a cooperative partner program with regional and national laboratory service providers. Learn more about Mainz Biomed (NASDAQ:MYNZ) and its activities by clicking on this link. Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Mainz Biomed NV. Market Jar Media Inc. has or expects to receive from Mainz Biomed NV’s Digital Marketing Agency of Record (Native Ads Inc.) eighty nine thousand seven hundred sixty four USD for 12 days (9 business days). 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Mainz Biomed NV’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Mainz Biomed NV’s industry; (b) market opportunity; (c) Mainz Biomed NV’s business plans and strategies; (d) services that Mainz Biomed NV intends to offer; (e) Mainz Biomed NV’s milestone projections and targets; (f) Mainz Biomed NV’s expectations regarding receipt of approval for regulatory applications; (g) Mainz Biomed NV’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Mainz Biomed NV’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Mainz Biomed NV’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Mainz Biomed NV’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Mainz Biomed NV’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) Mainz Biomed NV’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Mainz Biomed NV to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Mainz Biomed NV’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Mainz Biomed NV’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Mainz Biomed NV’s business operations (e) Mainz Biomed NV may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Mainz Biomed NV undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Mainz Biomed NV nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Mainz Biomed NV nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Mainz Biomed NV or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Mainz Biomed NV or such entities and are not necessarily indicative of future performance of Mainz Biomed NV or such entities. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

May 24, 2023 09:00 AM Eastern Daylight Time

Image

‘Ready for Ron’ Now ‘Ready to Win’

Ready for Ron

For more than a year, Ready for Ron, an independent group working to Draft Florida Governor Ron DeSantis to run for President, actively built support for his candidacy. A petition with more than 250,000 signatures (and a lawsuit against the Federal Election Commission to share it) tens of thousands of TV and online ads, along with millions of phone calls, mail pieces, and emails, and a grassroots and coalitions program has done its job - Governor Ron DeSantis is expected to soon announce he’s running for President. With Governor DeSantis about to become an official candidate, Ready for Ron is changing its name to ‘Ready to Win’ to reflect its singular mission to nominate and elect Ron DeSantis to win in 2024. “We spent an entire year running thousands of TV ads, millions of mailings, and tens of millions of online, email, and social connections to drive the narrative – Ron DeSantis will be our next President,” stated Ed Rollins, Ready to Win’s Chief Political Strategist. “We built an infrastructure. We completely changed the discussion. With a quarter million petition signers calling for him to run we are thrilled that we see our goal achieved - Ron DeSantis entering the Presidential race. He may well be the only leader who can defeat Joe Biden.” In addition to its outreach and engagement initiatives, Ready for Ron worked with Impact Social to analyze the online and social media discussion in relation to Ron DeSantis and Donald Trump among swing voters. The data clearly and consistently shows Ron DeSantis can beat Joe Biden, and Donald Trump simply can’t. Additional data research with multiple vendors covering more than 19 million voters affirms these findings. “Winning the nomination and the general election requires us all to work together to build this movement and save our nation,” stated Ready to Win Counsel, Dan Backer. “Our groundbreaking research debunked the bad polling plaguing Republicans for more than eight years. Using cutting edge massive data monitoring proves what everyone already knows - Donald Trump’s supporters are loyal and loud, but confined to only a sliver of the population that cannot grow. Moderate, swing, and independent voters are not coming back to Trump, ever, and he cannot possibly win the general Election – Ron DeSantis can.” “Voters young and old both know Governor DeSantis has a proven track record of standing up for America’s values. He is committed to defending the rights of parents, getting inflation and government spending under control, and solving the problems the radical left is causing. He dares to say no to the bullies, no matter how powerful they may seem. He can deliver safe streets, sane schools, and a soaring economy,” stated Gabriel Llanes, Executive Director of Ready to Win. “DeSantis is much more than a politician with savvy instincts; he is a public servant through and through. No ego to get in the way because he is about results.” “We will continue our ground-up grassroots efforts in key primary states, doing the hard work to train and mobilize a volunteer army to nominate, and elect, our next great American president,” Rollins continued. We feel DeSantis is well prepared to be the candidate to win the Republican nomination and beat President Biden. We are officially, Ready to Win!” ### For more information or to schedule an interview with a Ready to Win spokesperson, please contact Dan Rene at 202-329-8357 or dan@readyforron.com. Contact Details Ready to Win Dan Rene +1 202-329-8357 dan@readyforron.com Company Website https://www.readyforron.com/

May 23, 2023 02:50 PM Eastern Daylight Time

Emergent Health and Apollo Biowellness Announce Strategic Collaboration

Emergent Health Corp.

Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced today that it will be collaborating with Apollo Biowellness, Inc., the entity that Boustead has engaged to conduct an IPO of the roll up of the regenerative medicine space, previously announced by Emergent on May 18, 2023. Apollo is an aggregate of manufacturing, distribution and marketing of regenerative products and brands in the regenerative space. This partnership, along with the previously announced spin-off of PharmaZu will continue to build significant value to Emergent. As part of the roll-up being conducted by Boustead and Apollo Biowellness, effective June 1, 2023, Mr. Morrison will take over as President/CEO of Apollo Biowellness. Mr. Morrison will remain as a member of the Board of Directors of the Emergent and will assume the Title of Chairman of the Board. He will continue to be intimately involved with Emergent and the continued development, marketing and distribution of its products and brands, The two companies will coordinate marketing strategies, manufacturing and work together to expand the products and brands. Jim Morrison stated, “Since taking the helm of Emergent, I have enjoyed the process of creating the Company’s vibrant products and brands in the regenerative biologic space. The opportunity to coordinate between Emergent and Apollo and expand the value of these products and brands as President of Apollo Biowellness is an exciting opportunity and will bring expanded value to Emergent. I look forward to continuing to be involved in the dynamic offerings of Emergent going forward.” Jim Zimbler, a member of the Board of Directors, and previously the President of the Company, has been re-appointed as Interim President of the Company, also effective June 1, 2023. In addition to bringing on new senior management, the Company will be announcing a new CFO and a will conduct a new executive search for a new permanent full time CEO to work with the current management and Board and team and Mr. Morrison and the Apollo Biowellness team. The Company will announce more Management updates shortly. Jim Zimbler stated, “Jim Morrison has done a magnificent job during his tenure as President, and I know he will be a tremendous asset to Apollo Biowellness. I look forward to a close continued relationship with Mr. Morrison and leaning on him for his sizable experience and tutelage related to products and brands. That will greatly enhance the value Emergent will receive from the sale of Evolutionary Biologics and the other entities.” ABOUT EMERGENT HEALTH CORPORATION Emergent curates, develops and sells products in the Regenerative Health Space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. Its subsidiaries; PharmaZu, is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. For more information, please visit Emergent's Website and Social Media on Twitter. Before using any products, you should always consult with your Veterinarian and/or Family Doctor. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. FOR MORE INFORMATION, PLEASE CONTACT: Jim Morrison, Chairman of the Board James W. Zimbler – Interim President/Interim CEO Emergent Health Corporation Website i nfo@emergenthealthcompany.com Contact Details Emergent Health Corp. info@emergenthealthcompany.com Company Website https://emergenthealthcompany.com/

May 23, 2023 09:00 AM Eastern Daylight Time

The Humane Society of the United States Addresses the Pet Poverty Crisis

YourUpdateTV

Most people are aware of how poverty and structural inequality create challenges and barriers to accessing healthy food, education, jobs, health care and housing and how inflation is only making the crisis worse. Pet resources are no different. Many families are struggling to afford and access veterinary care, food and supplies for their beloved pets. More than 20 million pets live in poverty - three times as many pets live in poverty as enter shelters every year. This is a long overlooked national crisis exacerbated by inflation and the economy. Recently, Kitty Block, President and CEO of the Humane Society of the United States, participated in a nationwide satellite media tour to discuss the launch of the More Than a Pet campaign and how the organization is addressing the crisis. A video accompanying this announcement is available at: https://youtu.be/GdaZXktSjNI Over the past 20 years, the Humane Society of the United States has helped half a million pets and their families by providing veterinary care and supplies at no cost, keeping families and pets together in over 50 communities across the U.S. Without these services, families are often forced to make choices about sacrificing their own needs, even food and medications for themselves, to prioritize care for their pet. No family should ever have to make that choice. Since 2002, the Humane Society of United States’ Pets for Life and Rural Area Veterinary Services programs have been helping pet owners across the U.S. by providing food, supplies and services for their cats and dogs at no cost. It is critical to close the gap that exists for people and pets in underserved areas. With the new campaign called “More Than a Pet,” the HSUS is sounding an alarm about this crisis that is only getting worse. The Humane Society of the United States is offering these tips for people to support their communities: Advocate for keeping pets and their people together by signing the HSUS petition to close the pet equity gap. Your voice can make a big impact for all animals. Volunteer with the Humane Society of the United States’ Pets for Life and Rural Area Veterinary Services programs, which increase access to pet care for underserved communities. Donate pet food to your local shelter or pet food pantry. If you know of a neighbor in need, offer to help drive them to a veterinary appointment, foster their pet temporarily or provide a bag of their pet’s favorite food to help close the access to pet care gap. The HSUS is inviting the public to show their support for this campaign by sharing why their animal companion is #MoreThanAPet to them, at humanesociety.org/morethanapet. Campaign partner Smalls is donating a bowl of food for every photo shared, up to $1M, to pets and their families in need. Learn More and Get Involved About Kitty Block Kitty Block is the chief executive officer and president of the Humane Society of the United States and also chief executive officer of Humane Society International. She leads the nation's most effective animal protection organization in the fight for all animals. Block was named president and CEO of the Humane Society of the United States in January 2019, becoming the first woman to hold the position in the organization’s history. Block first joined the HSUS as a legal investigator in 1992 and was instrumental in bringing cruelties such as horse slaughter and the killing of dogs and cats for their fur in China to light. She led the HSUS’s efforts to secure protections for dolphins with successful litigation and landmark dolphin-safe tuna legislation. In addition, she was one of the architects of a successful lawsuit over commercial whaling brought against Japan by Australia in the International Court of Justice. She has served as an adviser to the White House on trade and the environment, and she has served multiple elected terms on the International Dolphin Conservation Agreement International Review Panel, which works with governments on monitoring violations of the agreement. Block received a law degree from The George Washington University in 1990 and a bachelor’s degree in communications and philosophy from the University of New Hampshire in 1986. She is a lifelong animal lover who helped her mother rescue and care for pets and other animals in need as a child. Block lives in Washington, D.C., with her husband and daughter, their street dog rescue, Lilly, and rescue cats, Misti and Storm Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

May 22, 2023 10:15 AM Eastern Daylight Time

Video

Consumer

M2Bio Sciences Division M2Biome Cardiometabolic Health Launches Website

Home "SMART" Home

Ripken Baseball® to Host All-Ripken Softball Games in Elizabethtown, Kentucky from July 27-30

National Association of REALTORS® Housing Market Update: Spring Homebuying Season Shows Steady Demand

ChillWell Launches ChillWell 2.0 Portable Air Cooler for Personal Space Chilling Benefits

BioNTech's mRNA Vaccine Shows Early Potential Against Pancreatic Cancer

‘Ready for Ron’ Now ‘Ready to Win’

Emergent Health and Apollo Biowellness Announce Strategic Collaboration

The Humane Society of the United States Addresses the Pet Poverty Crisis